New radioactive treatment shows promise for Hard-to-Treat tumors
NCT ID NCT06398444
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This study tests a radioactive drug (Lutetium-177) in 74 adults with advanced neuroendocrine tumors that cannot be removed by surgery and have gotten worse. The goal is to see if the drug is safe and can shrink or control the tumors. Participants receive the drug and are monitored for side effects and how long the cancer stays stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.